Exhibit 99.1 Company / Investor Contact: Tom Wirth EVP & CFO 610-832-7434 tom.wirth@bdnreit.com Brandywine Realty Trust Announces Fourth Quarter, Full Year 2025 Results and Initiates 2026 Guidance Philadelphia, PA, February 3, 2026 - Brandywine Realty Trust (NYSE:BDN) today reported its financial and operating results for the three and twelve-month periods ended December 31, 2025. Management Comments "We achieved many of our full year 2025 business plan objectives including tenant retention, same store NOI ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From _____ To _____ Commission File Number: 001-13836 JOHNSON CONTROLS INTERNATIONAL PLC (Exact name of registrant as specified in its charter) One Albert Quay, Cork, Irel ...

Financial Performance - Total sales for 2025 reached £32.7 billion, representing a 4% increase at AER and a 7% increase at CER[6] - Total operating profit surged to £7.9 billion, reflecting a growth of over 100% due to lower legal expenses and higher operating income[6] - Core operating profit increased by 11% to £9.8 billion, driven by growth in Specialty Medicines and Vaccines, alongside improved SG&A productivity[6] - GSK expects 2026 turnover growth between 3% to 5%, with core operating profit and core EPS both anticipated to grow by 7% to 9%[9] - Total turnover for 2025 reached £32,667 million, representing a 4% increase at AER and a 7% increase at CER, with Q4 2025 turnover at £8,618 million, up 6% at AER and 8% at CER[48] - Operating profit for 2025 was £7,932 million, a significant increase of 97% at AER and over 100% at CER, with Q4 2025 operating profit at £1,100 million, up 58% at AER and 65% at CER[63] - Core operating profit for 2025 was £9,783 million, reflecting a 7% increase at AER and an 11% increase at CER, with Q4 2025 core operating profit at £1,634 million, up 14% at AER and 18% at CER[50] - Total earnings per share (EPS) for 2025 was 141.1p, showing a greater than 100% increase, while Q4 2025 EPS was 15.8p, up 56%[69] - Core EPS for 2025 was 172.0p, an 8% increase, with Q4 2025 Core EPS at 25.5p, up 10%[69] Sales Growth by Segment - Specialty Medicines sales grew to £13.5 billion, up 17%, with significant contributions from Oncology (+43%) and Respiratory, Immunology & Inflammation (+18%)[6] - Respiratory, Immunology & Inflammation sales reached £3,810 million in 2025, growing by 15% year-over-year and 18% in Q4 2025, driven by Nucala and Benlysta[23] - Nucala sales grew at a double-digit rate globally, with US sales accelerating in Q4 2025 following its recent launch in COPD, despite ongoing pricing pressures[24] - Benlysta sales totaled £1,773 million in 2025, reflecting a 19% increase year-over-year and a 22% increase in Q4 2025, driven by strong demand and volume growth[25] - Oncology sales reached £1,977 million in 2025, with a 40% year-over-year growth, primarily driven by Jemperli and Ojjaara/Omjjara[26] - Jemperli sales grew to £861 million in 2025, marking an 84% increase year-over-year, supported by FDA and EMA approvals expanding its indication[27] - Vaccines sales totaled £9,157 million in 2025, with a 2% increase year-over-year, driven by strong demand for Shingrix and Meningitis vaccines[30] - Shingrix sales grew by 42% in Europe for the year, reflecting strong uptake and expanded public funding across several countries[31] - US sales of Shingrix decreased by 17% in 2025 due to challenges in activating unvaccinated consumers, with a cumulative immunization rate of 44%[33] - General Medicines sales were £10,036 million in 2025, reflecting a 4% decline year-over-year, with Trelegy sales growing by 11%[37] Research and Development - Research and development expenses totaled £7,525 million for 2025, an 18% increase at AER and 19% at CER, with Q4 2025 R&D expenses at £2,350 million, up 16% at AER and 17% at CER[55] - Five major FDA approvals were achieved in 2025, including Blenrep and Nucala for COPD, enhancing the product pipeline[10] - GSK has submitted regulatory applications for multiple products, including bepirovirsen for chronic hepatitis B in the US, EU, CN, and JP[89] - Anticipated pipeline milestones include regulatory decisions for depemokimab in H1 2026, indicating ongoing investment in R&D[88] - GSK completed the acquisition of IDRx, Inc. for a total consideration of US$1.1 billion (£840 million) and potential additional payments of up to US$150 million (£119 million) based on regulatory milestones[194] - GSK acquired BP Asset IX, Inc. for US$1.2 billion (£906 million) with additional success-based regulatory milestone payments of up to US$800 million (£588 million)[195] Shareholder Returns and Financial Management - GSK has initiated a £2 billion share buyback program, with £1.4 billion executed to date[14] - The company declared a dividend of 18p for Q4 2025 and expects to increase it to 70p for the full year 2026[13] - Cash generated from operations for 2025 was £8,943 million, an increase from £7,861 million in 2024, with Q4 2025 cash generation at £2,689 million[73] - Free cash inflow for 2025 was £4,029 million, a 41% increase from £2,863 million in 2024, with Q4 2025 free cash inflow at £960 million[77] - Dividends paid to shareholders increased to £2,564 million in 2025 from £2,444 million in 2024, a rise of 4.9%[141] Legal and Regulatory Matters - The effective tax rate for total results was 15.0% for 2025, while the core tax rate was 17.1%[66] - The Group's aggregate provision for legal and other disputes was £210 million as of 31 December 2025, a decrease from £1,446 million in 2024[160] - Significant legal charges and divestments included £367 million ($500 million) from settlements related to mRNA patent issues[123] Corporate Social Responsibility and Sustainability - GSK's commitment to responsible business includes making vaccines and medicines available at sustainable prices, with a focus on underserved populations[92] - GSK has pledged £6 million to the Global Fund to strengthen community-led responses to HIV, tuberculosis, and malaria, matched by the Gates Foundation for a total of £12 million[96] - GSK retained its position on the CDP 2025 A List for Climate Change and Water, ranking in the top 4% of companies assessed[96] - GSK's commitment to a net zero, nature-positive planet includes ambitious goals set for 2030 and 2045[92] Financial Position and Assets - Total assets increased to £61,118 million in 2025, up from £59,463 million in 2024, representing a growth of 2.8%[138] - Total equity increased to £15,956 million in 2025, up from £13,086 million in 2024, representing a growth of 21.6%[138] - Cash and cash equivalents at the end of 2025 were £3,397 million, down from £3,870 million at the end of 2024, a decrease of 12.2%[142] - The net surplus on the Group's pension plans improved to £229 million at 31 December 2025 from a net deficit of £103 million at 31 December 2024[188] Market Position and Future Outlook - GSK's 2031 sales outlook is projected to exceed £40 billion, supported by ongoing R&D investments and product launches[10] - The company plans to continue expanding its product offerings and market presence, focusing on innovative therapies and strategic acquisitions[143]

Revenue and Income - Total revenues for 2025 YTD reached $136,560 million, a decrease of 4.6% compared to $145,496 million in 2024 YTD[1] - Net income attributable to Phillips 66 for 2025 YTD was $4,403 million, down from $2,117 million in 2024 YTD, reflecting a significant increase of 107.5%[5] - Basic earnings per share for 2025 YTD was $10.82, compared to $5.01 in 2024 YTD, indicating a growth of 116.3%[1] - Total adjusted net income attributable to Phillips 66 for 2025 was $2.632 billion, compared to $2.604 billion in 2024, reflecting a slight increase[8] - Income before income taxes for 2025 YTD reached $4,500 million, a significant increase from $1,011 million in 2024 YTD[45] Expenses and Costs - Operating expenses for 2025 YTD totaled $6,423 million, a slight increase from $5,939 million in 2024 YTD, representing a rise of 8.1%[1] - The company’s total costs and expenses for 2025 YTD were $131,140 million, a decrease of 8.2% from $142,821 million in 2024 YTD[1] - Selling, general and administrative expenses for 2025 amounted to $1.088 billion, a decrease from $1.434 billion in 2024, representing a reduction of approximately 24.1%[65] Taxation - The effective tax rate for 2025 YTD was 16.5%, compared to 18.7% in 2024 YTD, indicating a decrease in the tax burden[3] - The effective tax rate on taxable U.S.-based special items was approximately 24%[15] - Adjusted effective tax rate for 2025 was 22.9%, up from 20.5% in 2024, indicating an increase in the adjusted tax rate[67] Segment Performance - The refining segment reported a loss of $274 million for 2025 YTD, an improvement from a loss of $365 million in 2024 YTD[5] - Marketing and Specialties segment generated $4,500 million in income for 2025 YTD, a substantial increase from $1,011 million in 2024 YTD, reflecting a growth of 344.4%[5] - Adjusted EBITDA for the Midstream segment in 2025 reached $3.773 billion, up from $3.662 billion in 2024, indicating a growth of approximately 3%[11] - The refining segment reported an adjusted EBITDA of $2.338 billion for 2025, a significant increase from $966 million in 2024[11] - The Chemicals segment's adjusted EBITDA for 2025 was $845 million, down from $1.348 billion in 2024, indicating a decline of approximately 37%[11] Cash Flow and Financing - Cash flows from operating activities for Q3 2025 were $187 million, with a year-to-date total of $2.752 billion[19] - The total net cash used in financing activities for Q3 2025 was $2.049 billion, reflecting significant debt repayments[19] - The company reported a cash and cash equivalents balance of $1.489 billion at the end of Q3 2025[20] - Total debt as of the end of 2025 was $19,716 million, a decrease from $21,755 million in 2024, indicating a reduction of approximately 9.5%[51] Asset Dispositions and Impairments - The company reported a net gain on dispositions of $2,984 million for 2025 YTD, compared to $321 million in 2024 YTD, showing a significant increase[1] - The company recorded a net gain on asset dispositions of $(68) million in Q1 2025, compared to a pre-tax impairment of $79 million in Q4 2025[29] - The total impairments recognized in 2025 reached $1.060 billion, with significant impacts in Q2 and Q3[19] - Special items included in income (loss) before income taxes totaled $1.841 billion for 2025, compared to a loss of $710 million in 2024, indicating significant fluctuations in special items[13] Production and Sales - Total refined products sales in the U.S. for Q1 2025 were 1,828 MB/D, up from 1,926 MB/D in Q1 2024, reflecting a 5% increase[45] - Total renewable fuels produced in Q1 2025 was 44 MB/D, a decrease from 63 MB/D in Q1 2024, showing a decline of 30%[48] - The worldwide total production, including proportional share of equity affiliates, was 1,871 MB/D year-to-date[43] Market Conditions - The Henry Hub natural gas price for Q1 2025 was $4.27 per MMBtu, significantly higher than $2.41 per MMBtu in Q1 2024, representing a 77.6% increase[26] - WTI crude oil price averaged $64.89 per barrel for the year-to-date, while Brent averaged $69.06[43] Legal and Regulatory Matters - The company reported a legal accrual of $605 million in Q3 2025, which was a notable increase from $262 million in Q2 2025[46] - The company incurred special items including a legal settlement of $(181) million and pending claims of $(123) million[58]

FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 333-82318 NOVO NORDISK A/S (Exact name of Reg ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-38776 FOX CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

Revenue Performance - For the three months ended December 31, 2025, total revenues increased by $104 million or 2% to $5,182 million compared to the same period in 2024, driven by higher distribution and advertising revenues [88]. - For the six months ended December 31, 2025, total revenues increased by $278 million or 3% to $8,920 million, attributed to higher distribution, advertising, and content revenues [92]. - Cable Network Programming segment revenues rose by $110 million or 5% for the three months ended December 31, 2025, driven by higher distribution, advertising, and content revenues [102]. - Television segment revenues decreased by $24 million or 1% for the three months ended December 31, 2025, primarily due to lower content revenues, despite higher advertising and distribution revenues [107]. - Television segment revenues increased by $73 million or 1% for the six months ended December 31, 2025, mainly due to higher advertising and distribution revenues [109]. Operating Expenses - Operating expenses for the three months ended December 31, 2025, increased by $119 million or 3% to $3,895 million, mainly due to higher sports programming rights amortization and production costs [90]. - Operating expenses for the six months ended December 31, 2025, increased by $185 million or 3% to $5,979 million, primarily driven by higher sports programming rights and digital content costs [93]. - Operating expenses for Cable Network Programming increased by $72 million or 5% for the three months ended December 31, 2025, primarily due to higher sports programming rights costs [103]. Net Income and EBITDA - Net income for the three months ended December 31, 2025, decreased by $141 million or 36% to $247 million, largely due to changes in the fair value of investments in equity securities [97]. - Adjusted EBITDA for Cable Network Programming decreased by $89 million or 11% for the three months ended December 31, 2025, reflecting the impact of increased expenses [101]. - Adjusted EBITDA for the three months ended December 31, 2025, was $692 million, compared to $781 million for the same period in 2024, representing a decrease of 11.4% [119]. - Corporate and Other EBITDA decreased by $57 million or 70% for the three months ended December 31, 2025, and by $119 million or 78% for the six months ended December 31, 2025, primarily due to costs associated with the launch of FOX One [114]. Cash Flow and Financial Position - The Company has approximately $2.0 billion in cash and cash equivalents as of December 31, 2025, along with an unused $1.0 billion revolving credit facility [120]. - Net cash used in operating activities for the six months ended December 31, 2025, was $(799) million, compared to $(204) million in 2024, indicating a significant increase in cash outflow [124]. - Net cash used in investing activities for the six months ended December 31, 2025, was $(393) million, up from $(240) million in 2024, primarily due to increased investments and capital expenditures [125]. - Net cash used in financing activities for the six months ended December 31, 2025, was $(2.142) billion, compared to $(553) million in 2024, largely due to stock repurchase activities [126]. Dividends and Acquisitions - The Company declared a semi-annual dividend of $0.28 per share, payable on March 25, 2026, with a record date of March 4, 2026 [128]. - The Company is evaluating potential acquisitions and dispositions of certain businesses and assets, which may involve cash or the assumption of additional indebtedness [123]. Credit Rating - The Company maintains a stable credit rating of Baa2 from Moody's and BBB from Standard & Poor's as of December 31, 2025 [130].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF ...

Customer Concentration and Sales - In 2025, sales to the top ten customers accounted for 74% of total revenue, with Customer A, B, and C contributing 31%, 17%, and 11% respectively[73] - The company relies on a small number of customers, with three customers accounting for over 10% of total net revenue, increasing vulnerability to customer loss[73] - The company is affected by seasonality, with the strongest sales typically occurring in the fourth quarter due to holiday-related demand[102] Cost and Pricing Pressures - Significant increases in raw material costs, particularly aluminum, negatively impacted results in 2025[78] - The company experienced fluctuations in raw material and energy costs, which represent a significant portion of the cost of sales[78] - Labor costs in the United States continue to rise, potentially impacting operating expenses and growth[84] - The company has implemented price increases, which may slow sales growth or create volume declines as customers react to these changes[99] Regulatory and Compliance Risks - Regulatory changes regarding environmental sustainability could materially affect sales and product offerings, particularly in the Hefty Tableware segment[87] - The lack of a uniform regulatory framework across the U.S. complicates compliance and impacts marketing and product development strategies[90] - The company is subject to various governmental regulations, which may incur material liabilities and compliance costs, potentially affecting its financial condition and operations[123] - Environmental, health, and safety laws impose strict liabilities that could lead to significant fines, penalties, and increased compliance costs, impacting profitability[124] - The company may face increased costs due to new regulations aimed at reducing plastic waste, which could affect demand for certain products[127] - Stakeholder focus on environmental issues, including climate change and sustainability, may hinder access to capital and impact consumer demand for products[128] Financial and Debt Management - As of December 31, 2025, the company had $1,586 million of outstanding indebtedness under its senior secured term loan facility maturing in 2032 and $693 million of borrowing capacity under its senior secured revolving credit facility maturing in 2029[118] - The unhedged portion of the Term Loan Facility was approximately $586 million as of December 31, 2025, exposing the company to interest rate risk[121] - Higher interest rates during the year ended December 31, 2023, increased the company's debt service obligations on unhedged variable rate indebtedness, leading to a decrease in net income and cash flows[122] - As of December 31, 2025, the company had significant variable rate debt commitments outstanding, accruing interest at the SOFR rate plus an applicable margin of 1.75%[292] - The aggregate notional amount of interest rate swaps in effect as of December 31, 2025, was $1,000 million, with fixed rates ranging from 2.66% to 3.40%[293] - Additional interest rate swaps with a notional value of $900 million were entered into, fixing the SOFR to an annual rate of 3.33% to 3.41%[294] - A 100-basis point increase in interest rates under the Term Loan Facility would result in a $6 million increase in interest expense per annum on outstanding borrowings[296] Competition and Market Dynamics - The company faces competitive pressures from both established and new entrants in the market, necessitating continuous innovation[75] - Economic downturns and inflationary pressures have historically led to decreased demand for products, impacting overall sales[92][94] Operational Challenges - Supply chain disruptions, including reduced trucking capacity, have led to increased transportation costs and operational challenges[82] - The company faces intense competition for qualified personnel, which could hinder its ability to conduct research and development activities[104] - The company has quality control measures in place, but any failure to maintain product safety and quality could result in recalls and harm to its reputation[100] - Cybersecurity threats pose risks to the company's IT and operational technology systems, which could disrupt operations and adversely impact financial results[134] Corporate Governance and Ownership - PFL controls approximately 74% of the company's outstanding shares, allowing it to determine the outcome of corporate actions requiring stockholder approval[150] - The concentration of PFL's ownership may discourage other parties from making tender offers, potentially preventing stockholders from receiving a premium for their shares[152] - The company is classified as a "controlled company" under Nasdaq rules, which allows it to rely on exemptions from certain corporate governance requirements[158] Legal and Insurance Risks - Legal claims and proceedings could require significant time and resources to defend, potentially affecting cash flows and financial condition[137] - The company maintains insurance for some risks, but may face uninsured liabilities that could adversely affect cash position and results of operations[141] Strategic Initiatives - The company may pursue acquisitions of brands, businesses, assets, or technologies, which could involve risks such as the assumption of contingent liabilities and potential impairments of acquired intangible assets[105] - The company intends to continue paying quarterly cash dividends on its common stock, but this ability may be limited by various factors including financial condition and capital requirements[148] - The company relies on effective systems to gather and use consumer data for marketing, with risks associated with new product development and market entry[98]

Revenue and Sales Performance - Revenue for Q4 2025 was $9.7 million, a 3% increase sequentially from $9.5 million in Q3 2025, but a 10% decrease year-over-year from $10.8 million in Q4 2024[5] - Full year 2025 net sales were $39.8 million, a 7% decrease compared to $43.0 million in 2024[5] Membership and Active Users - Active Members decreased to 26,650 as of December 31, 2025, down from 28,030 at September 30, 2025, and 30,870 at December 31, 2024[5] Profitability and Loss - Operating loss for Q4 2025 was $635,000, compared to $495,000 in Q3 2025 and $421,000 in Q4 2024; excluding restructuring charges, the loss would have been $352,000[5] - Net loss for Q4 2025 was $588,000, or $0.05 per diluted share, compared to a net loss of $431,000, or $0.04 per diluted share, in Q3 2025, and net income of $176,000, or $0.02 per diluted share, in Q4 2024[5] - Net income for 2025 was $(882) million, a decrease from $572 million in 2024[18] Cash Flow and Liquidity - Total cash, cash equivalents, and marketable securities were $28.9 million as of December 31, 2025, down from $32.0 million as of September 30, 2025[11] - Operating cash flow for Q4 2025 was a net outflow of $959,000, compared to a net inflow of $88,000 in Q4 2024[11] - Net cash used in operating activities increased to $(5,997) million in 2025 from $(3,367) million in 2024[18] - Total cash, cash equivalents, and restricted cash decreased to $6,820 million at the end of 2025 from $13,567 million at the end of 2024[18] Dividends and Shareholder Returns - The company declared a quarterly cash dividend of $0.10 per share, payable on February 27, 2026[11] - Dividends paid remained consistent at approximately $(9,210) million for both 2025 and 2024[18] Inventory and Assets - Inventories increased to $1,274 million in 2025 from $1,000 million in 2024[18] - Other current assets showed a significant change, increasing to $1,224 million in 2025 from $(113) million in 2024[18] - Right-of-use assets obtained in exchange for operating lease liabilities rose to $487 million in 2025 from $124 million in 2024[18] Cost Management and Restructuring - The company expects to realize $1.5 million in annualized cost savings from restructuring initiatives that are substantially complete[4] - The company relocated about 40% of its product sourcing base from America to East Asia to reduce tariff uncertainty and streamline logistics[4] Cash Flow from Investments - Cash flows from investing activities provided $8,148 million in 2025, contrasting with $(30,075) million used in 2024[18] - Purchases of marketable securities decreased to $(50,742) million in 2025 from $(70,431) million in 2024[18] Foreign Exchange Impact - The effect of exchange rates on cash resulted in a gain of $312 million in 2025 compared to $5 million in 2024[18]